Trial Profile
A Phase 2 Evaluation of the Monoclonal Antibody, RAV12, in Combination With Standard Gemcitabine in the Treatment of Patients With Metastatic Pancreatic Cancer Who Have Not Been Previously Treated for Metastatic Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs RAV 12 (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- 18 Apr 2012 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 18 Apr 2012 Company (MacroGenics) added and actual patient number is 2 as reported by ClinicalTrials.gov.
- 18 Apr 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.